Talquetamab & STOP-CA
Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity. STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988
Aug 10, 2023•15 min
OncoPharm
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Ruby Trial & Quizartinib Toxicity
The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.
Aug 03, 2023•14 min
BCOP Study Tips
By listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.
Jul 27, 2023•14 min
Chemotherapy Sequencing In Colorectal Cancer
A Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI. Some interesting dosing to discuss in this study. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692
Jul 20, 2023•14 min
Phase 1 Clinical Trials In Oncology with Dr. Donald Harvey
We welcome Dr. Donald Harvey to the podcast to discuss Phase 1 clinical trials in oncology. Topics include goals of Phase 1 trials, how these early studies are conducted, how doses are determined, and some limitations of current practices.
Jul 13, 2023•39 min
Investigational Drug Services In Oncology with Dr. Jackie Saunders
We welcome Jacqueline (Jackie) Saunders to the podcast to talk about investigational drug services (IDS) in oncology and how pharmacists manage the storage, preparation, & delivery of experimental drugs.
Jul 06, 2023•29 min
NADIM II & Favorable Risk RCC
This episode... More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II. Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.) NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530 FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030
Jun 29, 2023•15 min
Glofitamab & TALAPRO - 2
This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide. TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3
Jun 22, 2023•13 min
ASCO '23 Entrees
We highlight notable data from this month's ASCO annual meeting. 1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC 2. ADAURA OS results and low rate of osimertinib use in control arm 3. Keynote 671: perioperative pembrolizumab in NSCLC 4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer? 5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+) 6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease) 7. CARTITUDE-4: Cilta-Cel earli...
Jun 15, 2023•28 min
ASCO '23 Appetizers
ASCO '23 Appetizers by John Bossaer
Jun 08, 2023•12 min
PROpel and Cilostazol to Prevent Paclitaxel Neuropathy
Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population. Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol? PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043 Cilostazol RCT: https://doi.org/10.1002/phar.2830 Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514
Jun 01, 2023•17 min
Epcoritamab
We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.
May 25, 2023•16 min
Trimodality Treatment For Bladder Cancer
A recent paper serves as a good prompt to discuss trimodality treatment for muscle-invasive bladder cancer and the data supporting its use. Zlotta et al: https://doi.org/10.1016/S1470-2045(23)00170-5
May 18, 2023•16 min
GAIA-CLL13 & COSMIC-313
Today's Pod discusses... 1) A large trial comparing 4 different CLL treatments GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093 2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851 3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809
May 11, 2023•23 min
SUNLIGHT
Talking 3rd-line treatment of metastatic colon cancer. Tipiracil-trifluridine + bevacizuamb vs. tipiracil-trifluridine alone. And a bit on the theory of "bevacizumab beyond progression." SUNLIGHT: https://www.nejm.org/doi/full/10.1056/NEJMoa2214963
May 04, 2023•13 min
QuANTUM First (Quizartinib 1st Line in AML)
Quizartinib vs. Placebo(?) + Chemo in newly diagnosed AML. We add a bit of context about quizartinib's history leading up to this study preview possible role in therapy if approved in the future. Link: https://doi.org/10.1016/S0140-6736(23)00464-6
Apr 27, 2023•19 min
ICI + Bacterial Supplementation
We take a peak at an intriguing study (n = 29) that gave some metastatic RCC patients receiving nivolumab + ipilimumab a supplement of a bacterium (n = 19) and a control group. We discuss what to look for in the future studies that are likely to follow with similar methods.
Apr 20, 2023•12 min
Neoadjuvant Chemo In Breast Cancer
The Landmarks of OncoPharm series returns to discuss NSABP's B18 story of neoadjuvant vs. adjuvant AC in stages I & II breast cancer from 1998. B18: https://pubmed.ncbi.nlm.nih.gov/?term=36989610 Flashback Flashforeward: https://pubmed.ncbi.nlm.nih.gov/?term=36989608
Apr 13, 2023•13 min
Olanzapine & Pembrolizumab (endometrial, urothelial) Updates
Lots of updates: Olanzapine increases weight gain, QOL in some advanced cancer: https://pubmed.ncbi.nlm.nih.gov/?term=36977285 Chemotherapy Toxicity - When Less is More: https://www.nejm.org/doi/full/10.1056/NEJMcibr1202395 Pembro + Chemo improves PFS > chemo alone in advanced endometrial cancer: https://www.nejm.org/doi/full/10.1056/NEJMoa2302312 Enfortumab vedotin + pembrolizumab gets an accelerated approval for cisplatin-ineligible patients with urothelial carcinoma. Safety signals seen....
Apr 06, 2023•20 min
[Re-release] Tales of Brave Iressa (2017)
With new Pod this week, we're re-releasing the 2nd episode from way back in 2017 that provides a historical overview of how the use of EGFR TKIs changed from their use in all NSLCLC to only with activating mutations.
Mar 30, 2023•17 min
Linezolid vs. Vanc In Neutropenic Fever
Not that you always need extended gram positive coverage, but if you did... As is often the case with this Pod, this is mostly providing historical context. Link: https://doi.org/10.1086/500139
Mar 23, 2023•12 min
Chemo-Induced Ovarian Dysfunction
Prompted by a recent JCO review article (link below), it seemed like a good idea to discuss risks of ovarian dysfunction in women of childbearing potential, what drugs have the highest risk, and fertility preservation techniques. Review article: https://pubmed.ncbi.nlm.nih.gov/?term=29620997 Cyclophosphamide dose equivalent calculator: https://www.oncofertilityrisk.com/CED.html
Mar 16, 2023•12 min
S1801 (Neoadjuvant Pembro In Melanoma)
We review a clever study looking at neoadjvuant & adjuvant pembrolizumab vs. only adjuvant pembrolizumab in melanoma. Link: 10.1056/NEJMoa2211437 We also discuss some updates on abemaciclib and osimertinib
Mar 09, 2023•11 min
DA-EPOCH (R)
Landkarmks of OncoPharm: Dose-Adjusted EPOCH (+ R) This episode focuses on the pharmacodynamic rationale for the protocol and delivery, not so much the details of the literature supporting its use. Wilson et al 2002, Blood: https://doi.org/10.1182/blood.V99.8.2685
Mar 02, 2023•11 min
Cannabis Use With ICIs
Cannabinoids appear to impact immune system function, so could cannabis use blunt the effect of immune checkpoint inhibitors? I don't know, brah. Maybe? Review: https://pubmed.ncbi.nlm.nih.gov/?term=35749680 Cannabis associated with poorer ORR: https://doi.org/10.1634/theoncologist.2018-0383 Cannabis associated with poorer TTP & OS: https://doi.org/10.3390/cancers12092447
Feb 24, 2023•11 min
Instant KarMMa
Ide-Cel vs. "standard" treatment in relapsed/refreactory multiple myeloma study - the KarMMa-3 trial - is discussed. Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2213614
Feb 16, 2023•12 min
CodeBreak200 And Elderly AML Survival
CodeBreak200: docetaxel vs. sotorasib in 2nd-line metastatic NSCLC (KRAS-G12C). A new safety signal emerges. https://doi.org/10.1016/S0140-6736(23)00221-0 A new survival prediction model for elderly patients with AML not receiving intensive therapy. https://doi.org/10.1002/cncr.34609
Feb 09, 2023•20 min
Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.
Feb 02, 2023•18 min
HER2 Targeting Era Of Colorectal Cancer Begins
Tucatinib's FDA-approval (with trastuzumab) for HER2 amplified metastatic colorectal cancer launches a new era of targeted therapy in colorectal cancer. Targeting HER2 (amplified in ~3-5% of advanced colorectal cancers) in colorectal cancer will likely evolve over the coming years, so a brief history on how it has evolved so far may be helpful.
Jan 26, 2023•11 min
Adjuvant Interferon In Melanoma
The Landmarks in OncoPharm series returns to discuss adjuvant interferon in melanoma. ECOG 1684: https://pubmed.ncbi.nlm.nih.gov/?term=36649675 Commentary on E1684: https://ascopubs.org/doi/abs/10.1200/JCO.22.02354
Jan 19, 2023•13 min
For the best experience, listen in Metacast app for iOS or Android